Wedge Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Wedge Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.81M	Buy	+380,801	New	+$3.44M	0.06%	233

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Wedge Capital Management's BCRX Position: Q2 2026 in Review

Wedge Capital Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 380,801 shares worth $3.81M. The stake represents 0.06% of the portfolio and ranks #233 among its holdings.

318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Wedge Capital Management held 380,801 shares of BioCryst Pharmaceuticals worth $3.81M as of Q2 2026.
BioCryst Pharmaceuticals was a new Wedge Capital Management position in Q2 2026.
BioCryst Pharmaceuticals made up 0.06% of Wedge Capital Management's portfolio in Q2 2026, its #233 holding.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.